Phathom Pharmaceuticals (PHAT) Short term Debt (2020 - 2021)
Phathom Pharmaceuticals' (PHAT) quarterly Short term Debt came in at $10.3 million in Q2 2021, up 644.78% year-on-year from $1.4 million in Q2 2020, and down 12.07% on a QoQ basis from $11.8 million in Q1 2021.
Phathom Pharmaceuticals (PHAT) Short term Debt (2020 - 2021) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 2 years of Short term Debt data on file, last reported at $10.3 million in Q2 2021.
- On a quarterly basis, Short term Debt rose 644.78% year-over-year to $10.3 million in Q2 2021; TTM through Jun 2021 was $10.3 million, a 644.78% increase from a year earlier, with the FY2020 full-year figure at $7.4 million, changed N/A from the prior year.
- Short term Debt for Q2 2021 stood at $10.3 million, down from $11.8 million in the prior quarter.
- Over the last five years, Short term Debt for PHAT reached as high as $11.8 million in Q1 2021 and fell as low as $1.4 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Phathom Pharmaceuticals | 951.79 Mn | 768.02 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 10.35 Mn |
| Mar 31, 2021 | 11.77 Mn |
| Dec 31, 2020 | 7.35 Mn |
| Sep 30, 2020 | 5.56 Mn |
| Jun 30, 2020 | 1.39 Mn |